The Etiology of New-onset Status Epilepticus
NCT05647525 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60
Last updated 2022-12-15
Summary
This study will help to identify the causes of new epilepsy and provide a basis for the development of a rational and standardized diagnosis and treatment plan to reduce the rate of disability and death.
Conditions
- Status Epilepticus
Interventions
- DIAGNOSTIC_TEST
-
Perform autoimmune encephalitis titer tests
We only follow up without intervention.
Sponsors & Collaborators
-
Jie Liu
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-01-01
- Primary Completion
- 2022-08-30
- Completion
- 2022-09-30
Countries
- China
Study Locations
More Related Trials
-
Safety Study of GNbAC1 Monoclonal Antibody in Healthy Male Volunteers
NCT02452996 ·Status: COMPLETED ·Phase: PHASE1
-
Application of Multiparametric Structural and Functional MRI in Unraveling the Substrates of Cognitive Impairment and Disability in Multiple Sclerosis
NCT06653283 ·Status: NOT_YET_RECRUITING
-
Progression of Cognitive and Physical Symptoms in Multiple Sclerosis
NCT00922831 ·Status: WITHDRAWN
-
Severe Acute Respiratory Syndrome Coronavirus Type 2 (SARS-CoV-2)-Related Multiple Sclerosis (MS) Vaccination Study
NCT05197699 ·Status: TERMINATED
-
Pathological Basis of MRI Signal Changes in Multiple Sclerosis
NCT02659956 ·Status: RECRUITING
-
Measuring Active Microglia in Progressive Multiple Sclerosis
NCT02207075 ·Status: COMPLETED
-
Multimodal Exploration of Patients With Multiple Sclerosis for an Early Detection of Subtle Progression
NCT05941975 ·Status: RECRUITING ·Phase: NA
-
A Study of GB261 in Systemic Sclerosis
NCT07159009 ·Status: NOT_YET_RECRUITING ·Phase: EARLY_PHASE1
-
A Longitudinal Study of Brain Atrophy in MS Patients Over 5 Years
NCT01847287 ·Status: COMPLETED
-
Alemtuzumab on Surrogate Markers of Disease Activity and Repair Using Advanced MRI Measures in Subjects With Relapsing Remitting Multiple Sclerosis
NCT01395316 ·Status: COMPLETED ·Phase: PHASE4
-
Neurocognitive Changes in Patients With Remitting Relapsing Multiple Sclerosis Treated With Natalizumab
NCT01250678 ·Status: UNKNOWN
-
Motor Evoked Potentials as a Biomarker in Alemtuzumab Treated Multiple Sclerosis Patients
NCT02623946 ·Status: COMPLETED
-
Magnetic Resonance Imaging (MRI) to Evaluate Activity of Multiple Sclerosis (MS)
NCT00001248 ·Status: RECRUITING
-
Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple Sclerosis
NCT01416155 ·Status: COMPLETED ·Phase: PHASE2
-
A Maintenance Extension of Phase I Pilot Study of Chimeric Anti-CD4 Antibody M-T412 in Patients With Multiple Sclerosis
NCT00004816 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Investigate the Radiological Onset of Action After Treatment Initiation With Subcutaneous (SC) Natalizumab in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
NCT05532163 ·Status: TERMINATED ·Phase: PHASE4
-
China National Registry of Neuro-Inflammatory Diseases
NCT05154370 ·Status: RECRUITING
-
Natalizumab Subcutaneous Immunogenicity and Safety Study
NCT02142192 ·Status: TERMINATED ·Phase: PHASE2
-
Natalizumab Treatment of Progressive Multiple Sclerosis
NCT01077466 ·Status: COMPLETED ·Phase: PHASE2
-
Sema 4A as a Marker for Inflammatory Disease in Multiple Sclerosis
NCT05077956 ·Status: WITHDRAWN
-
Clinical Disease Activity With Long Term Natalizumab Treatment
NCT02677077 ·Status: COMPLETED
-
Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
NCT04380220 ·Status: UNKNOWN
-
Study of Empathy in MS
NCT05332951 ·Status: COMPLETED
-
Mechanisms of Disease Severity in Multiple Sclerosis: an Integrative Multimodal Study
NCT03369106 ·Status: ACTIVE_NOT_RECRUITING
-
A Study to Evaluate LY3154207 on the Brain of Healthy Participants
NCT04258826 ·Status: COMPLETED ·Phase: PHASE1